Loading...

Heidelberg Pharma

DB:WL6
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
WL6
DB
€88M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Heidelberg Pharma AG, through its subsidiaries, operates as a biopharmaceutical company that focuses on oncology and antibodies, and specializes in antibody drug conjugates (ADCs) in Germany, Europe, the United States, China, and Australia. The last earnings update was 14 days ago. More info.


Add to Portfolio Compare Print
WL6 Share Price and Events
7 Day Returns
-2.5%
DB:WL6
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
16.9%
DB:WL6
-5.6%
DE Biotechs
-4.5%
DE Market
WL6 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Heidelberg Pharma (WL6) -2.5% 3.3% 18.6% 16.9% 75.6% -7%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • WL6 outperformed the Biotechs industry which returned -5.6% over the past year.
  • WL6 outperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
WL6
Industry
5yr Volatility vs Market

WL6 Value

 Is Heidelberg Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Heidelberg Pharma. This is due to cash flow or dividend data being unavailable. The share price is €3.12.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Heidelberg Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Heidelberg Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:WL6 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-02-28) in EUR €-0.39
DB:WL6 Share Price ** DB (2019-04-25) in EUR €3.12
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Heidelberg Pharma.

DB:WL6 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DB:WL6 Share Price ÷ EPS (both in EUR)

= 3.12 ÷ -0.39

-7.91x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Heidelberg Pharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Heidelberg Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Heidelberg Pharma's expected growth come at a high price?
Raw Data
DB:WL6 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.91x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
12.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Heidelberg Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Heidelberg Pharma's assets?
Raw Data
DB:WL6 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-02-28) in EUR €0.81
DB:WL6 Share Price * DB (2019-04-25) in EUR €3.12
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:WL6 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DB:WL6 Share Price ÷ Book Value per Share (both in EUR)

= 3.12 ÷ 0.81

3.83x

* Primary Listing of Heidelberg Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Heidelberg Pharma is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Heidelberg Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Heidelberg Pharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

WL6 Future Performance

 How is Heidelberg Pharma expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Heidelberg Pharma expected to grow at an attractive rate?
  • Unable to compare Heidelberg Pharma's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Heidelberg Pharma's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Heidelberg Pharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:WL6 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:WL6 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 12.4%
DB:WL6 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 16.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:WL6 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:WL6 Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-11-30 7 -9 1
2020-11-30 8 -9 3
2019-11-30 6 -10 -11 1
DB:WL6 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-02-28 5 -10 -12
2018-11-30 4 -10 -12
2018-08-31 4 -10 -11
2018-05-31 3 -8 -11
2018-02-28 2 -9 -11
2017-11-30 2 -8 -11
2017-08-31 3 -7 -10
2017-05-31 2 -8 -8
2017-02-28 2 -7 -7
2016-11-30 2 -7 -6
2016-08-31 2 -6 -7
2016-05-31 2 -5 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Heidelberg Pharma is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Heidelberg Pharma's revenue is expected to grow by 16.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:WL6 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Heidelberg Pharma Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:WL6 Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-11-30 -0.32 -0.32 -0.32 1.00
2020-11-30 -0.33 -0.33 -0.33 1.00
2019-11-30 -0.37 -0.37 -0.37 1.00
DB:WL6 Past Financials Data
Date (Data in EUR Millions) EPS *
2019-02-28 -0.39
2018-11-30 -0.41
2018-08-31 -0.44
2018-05-31 -0.60
2018-02-28 -0.69
2017-11-30 -0.76
2017-08-31 -0.73
2017-05-31 -0.63
2017-02-28 -0.58
2016-11-30 -0.53
2016-08-31 -0.64
2016-05-31 -0.69

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Heidelberg Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Heidelberg Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Heidelberg Pharma has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

WL6 Past Performance

  How has Heidelberg Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Heidelberg Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Heidelberg Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Heidelberg Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Heidelberg Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Heidelberg Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Heidelberg Pharma Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:WL6 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-02-28 4.69 -12.34 3.22 11.57
2018-11-30 4.09 -11.67 3.16 10.68
2018-08-31 3.91 -10.77 3.13 10.26
2018-05-31 3.17 -11.42 3.13 10.44
2018-02-28 2.24 -11.42 2.96 9.76
2017-11-30 2.12 -10.97 2.95 9.32
2017-08-31 2.65 -9.89 2.71 8.24
2017-05-31 1.72 -8.26 2.39 6.84
2017-02-28 2.26 -7.27 2.30 6.44
2016-11-30 2.13 -6.39 2.18 6.12
2016-08-31 2.09 -7.13 4.08 5.63
2016-05-31 1.76 -7.04 4.39 5.28
2016-02-29 2.26 -6.56 4.61 4.94
2015-11-30 2.70 -6.55 4.85 4.44
2015-08-31 2.75 -4.84 3.49 4.53
2015-05-31 5.02 -3.21 3.40 4.28
2015-02-28 4.36 -3.89 3.37 4.39
2014-11-30 3.87 -5.70 3.66 5.57
2014-08-31 6.80 -5.49 6.24 4.87
2014-05-31 8.65 -5.89 6.76 5.92
2014-02-28 11.14 -5.95 7.32 7.29
2013-11-30 14.06 -5.04 7.96 8.09
2013-08-31 15.51 -5.93 3.96 2.32
2013-05-31 16.16 -7.32 4.54 3.21
2013-02-28 16.39 -8.81 5.13 4.15
2012-11-30 16.78 -9.39 4.86 4.70
2012-08-31 17.75 -8.12 6.46 1.61
2012-05-31 16.97 -8.91 5.95 3.62

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Heidelberg Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Heidelberg Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Heidelberg Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Heidelberg Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Heidelberg Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

WL6 Health

 How is Heidelberg Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Heidelberg Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Heidelberg Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Heidelberg Pharma has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Heidelberg Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Heidelberg Pharma has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Heidelberg Pharma Company Filings, last reported 1 month ago.

DB:WL6 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-02-28 22.92 0.00 16.07
2018-11-30 25.89 0.00 19.44
2018-08-31 30.01 0.00 22.71
2018-05-31 32.55 0.00 25.54
2018-02-28 34.64 0.00 27.15
2017-11-30 37.02 0.00 30.38
2017-08-31 7.21 3.88 4.49
2017-05-31 10.54 3.82 5.50
2017-02-28 7.82 3.77 2.57
2016-11-30 9.76 3.75 4.57
2016-08-31 11.99 0.00 3.27
2016-05-31 13.70 0.00 5.14
2016-02-29 10.88 0.00 2.30
2015-11-30 9.48 0.00 1.31
2015-08-31 12.49 0.00 3.07
2015-05-31 14.13 0.01 4.10
2015-02-28 10.81 0.01 1.37
2014-11-30 11.88 0.08 2.20
2014-08-31 13.16 0.07 2.82
2014-05-31 10.57 2.63 2.83
2014-02-28 12.08 2.60 5.55
2013-11-30 14.95 2.75 8.92
2013-08-31 16.04 2.78 9.88
2013-05-31 16.44 2.79 12.89
2013-02-28 17.97 2.80 17.67
2012-11-30 19.92 2.98 23.36
2012-08-31 21.45 2.99 28.68
2012-05-31 -0.28 10.70 2.92
  • Heidelberg Pharma has no debt.
  • Heidelberg Pharma has no debt compared to 5 years ago when it was 21.5%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Heidelberg Pharma has sufficient cash runway for 1.4 years based on current free cash flow.
  • Heidelberg Pharma has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 23.5% each year.
X
Financial health checks
We assess Heidelberg Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Heidelberg Pharma has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

WL6 Dividends

 What is Heidelberg Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Heidelberg Pharma dividends. Estimated to be 0% next year.
If you bought €2,000 of Heidelberg Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Heidelberg Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Heidelberg Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:WL6 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:WL6 Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2021-11-30 0.00 1.00
2020-11-30 0.00 1.00
2019-11-30 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Heidelberg Pharma has not reported any payouts.
  • Unable to verify if Heidelberg Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Heidelberg Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Heidelberg Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Heidelberg Pharma's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Heidelberg Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Heidelberg Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Heidelberg Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

WL6 Management

 What is the CEO of Heidelberg Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jan Schmidt-Brand
COMPENSATION €313,104
AGE 60
CEO Bio

Dr. Jur. Jan Schmidt-Brand has been the Chief Financial Officer of Wilex AG since September 01, 2012 and serves as its Member of The Executive Management Board and Chief Executive Officer. Dr. Jur. Schmidt-Brand has been Chief Executive Officer of Heidelberg Pharma AG since December 2006 and has been its Chief Financial Officer since September 2001. He has been Managing Director of WILEX's subsidiary Heidelberg Pharma GmbH since September 1, 2012. He served as Executive Vice President of Administration at Heidelberg Pharma AG. He held several positions at the BASF Group for a total of eight years, as an executive in the central tax department with a general commercial power of attorney ('Prokurist'). He serves as Head of the Finance and Tax working group. Dr. Jur. Schmidt-Brand served as an Executive Vice President of Finance at Heidelberg Pharma AG. He served as Managing Director of Heidelberg Pharma Holding GmbH & Co. KG. Prior to Heidelberg, he served as Chief Financial Officer since September 2001 and Managing Director of EBEWE Arzneimittel GmbH, an Austrian pharmaceutical firm within BASF Pharma from 1997 to 2001. In EBEWE Arzneimittel GmbH, he managed the marketing, sales, finance and administrative areas and was responsible for the successful launch of the innovative antiobesity drug Reductil™ and the redesign of EBEWE's strategy within BASF Pharma. He was employed at BASF AG and Knoll AG in various legal, tax and controlling roles and was engaged in several corporate restructuring as well as merger and acquisition projects. He is a member of the Board of BioDeutschland. Dr. Jur. Schmidt-Brand received degrees in law and business administration from the University of Bayreuth, Mannheim and Geneva, respectively. He holds a doctorate in law.

CEO Compensation
  • Jan's compensation has increased whilst company is loss making.
  • Jan's remuneration is higher than average for companies of similar size in Germany.
Management Team

Jan Schmidt-Brand

TITLE
CEO, CFO & Member of the Executive Management Board
COMPENSATION
€313K
AGE
60

Andreas Pahl

TITLE
Chief Scientific Officer
COMPENSATION
€286K
TENURE
2.8 yrs

Sylvia Wimmer

TITLE
Manager of Corporate Communications
Board of Directors Tenure

Average tenure and age of the Heidelberg Pharma board of directors in years:

7.8
Average Tenure
51
Average Age
  • The tenure for the Heidelberg Pharma board of directors is about average.
Board of Directors

Christof Hettich

TITLE
Chairman of Supervisory Board
COMPENSATION
€53K
TENURE
8.6 yrs

Georg Baur

TITLE
Deputy Chairman of the Supervisory Board
COMPENSATION
€42K

Friedrich von Bohlen und Halbach

TITLE
Member of the Supervisory Board
COMPENSATION
€27K
AGE
56
TENURE
13.9 yrs

Birgit Kudlek

TITLE
Member of the Supervisory Board
COMPENSATION
€27K
AGE
51
TENURE
6.9 yrs

Mathias Hothum

TITLE
Member of the Supervisory Board
COMPENSATION
€25K
AGE
51
TENURE
3.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Heidelberg Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Heidelberg Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

WL6 News

Simply Wall St News

What Kind Of Shareholder Owns Most Heidelberg Pharma AG (FRA:WL6) Stock?

If you want to know who really controls Heidelberg Pharma AG (FRA:WL6), then you'll have to look at the makeup of its share registry. … Heidelberg Pharma is not a large company by global standards. … Taking a look at our data on the ownership groups (below), it's seems that.

Simply Wall St -

Should Heidelberg Pharma Be Disappointed With Their 72% Profit?

Heidelberg Pharma isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. … Over the last three years Heidelberg Pharma has grown its revenue at 8.1% annually.

Simply Wall St -

How Financially Strong Is Heidelberg Pharma AG (FRA:WL6)?

Heidelberg Pharma AG (FRA:WL6), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … I will take you through a few basic checks to assess the financial health of companies with no debt. … Is financial flexibility worth the lower cost of capital

Simply Wall St -

What Kind Of Shareholder Appears On The Heidelberg Pharma AG's (FRA:WL6) Shareholder Register?

A look at the shareholders of Heidelberg Pharma AG (FRA:WL6) can tell us which group is most powerful. … With a market capitalization of €75m, Heidelberg Pharma is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Heidelberg Pharma

Simply Wall St -

Is Heidelberg Pharma AG's (FRA:WL6) Balance Sheet Strong Enough To Weather A Storm?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is financial flexibility worth the lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

What You Must Know About Heidelberg Pharma AG's (FRA:WL6) Major Investors

In this article, I'm going to take a look at Heidelberg Pharma AG’s (FRA:WL6) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … Ownership structure has been found to have an impact on shareholder returns in both short- and long-term. … See our latest analysis for Heidelberg Pharma

Simply Wall St -

Market Sentiment Around Loss-Making Heidelberg Pharma AG (FRA:WL6)

Heidelberg Pharma AG's (FRA:WL6):. … Heidelberg Pharma AG, through its subsidiaries, operates as a biopharmaceutical company that focuses on oncology and antibodies, and specializes in antibody drug conjugates (ADCs) in Germany, Europe, the United States, China, and Australia. … The company’s loss has recently broadened since it announced a -€10.97m loss in the full financial year, compared to the latest trailing-twelve-month loss of -€11.42m, moving it further away from breakeven?

Simply Wall St -

Heidelberg Pharma AG (FRA:WL6): Does The Earnings Decline Make It An Underperformer?

DB:WL6 Income Statement Mar 20th 18 We can further examine Heidelberg Pharma's loss by looking at what the industry has been experiencing over the past few years. … Each year, for the past five years Heidelberg Pharma has seen an annual decline in revenue of -27.17%, on average. … The most useful step is to examine company-specific issues Heidelberg Pharma may be facing and whether management guidance has steadily been met in the past.

Simply Wall St -

WL6 Company Info

Description

Heidelberg Pharma AG, through its subsidiaries, operates as a biopharmaceutical company that focuses on oncology and antibodies, and specializes in antibody drug conjugates (ADCs) in Germany, Europe, the United States, China, and Australia. It is developing HDP-101, an antibody targeted amanitin conjugate (ATAC) candidate for the treatment of multiple myeloma; PSMA, an ATAC candidate to treat prostate cancer; CD19, an ATAC candidate for the treatment of haematological tumors; HuMAB 5B1, an ATAC candidate to treat metastatic pancreatic cancer; and NN, an ATAC candidate for treating leukemia. The company is also developing MESUPRON, an oral Urokinase-type plasminogen activator (uPA)/serine protease inhibitor to block the activity of tumor-relevant serine proteases, such as uPA, plasmin, and thrombin to prevent tumor growth and metastasis; REDECTANE, a diagnostic antibody for the treatment of clear cell renal cell carcinoma; and RENCAREX, a therapeutic antibody for the treatment of clear cell renal cell carcinoma. It also provides preclinical contract services. Heidelberg Pharma AG has strategic alliances with Bayer Corporation and Centocor Inc; collaboration agreement with Advanced Proteome Therapeutics Corporation; and a research agreement with Magenta Therapeutics Inc. for the development of antibody drug conjugates. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.

Details
Name: Heidelberg Pharma AG
WL6
Exchange: DB
Founded: 1997
€87,808,843
28,143,860
Website: http://heidelberg-pharma.com
Address: Heidelberg Pharma AG
Schriesheimer Strasse 101,
Ladenburg,
Baden-Württemberg, 68526,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DB WL6 Common Stock Deutsche Boerse AG DE EUR 13. Nov 2006
XTRA WL6 Common Stock XETRA Trading Platform DE EUR 13. Nov 2006
LSE 0QW5 Common Stock London Stock Exchange GB EUR 13. Nov 2006
Number of employees
Current staff
Staff numbers
60
Heidelberg Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 21:02
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/11
Last earnings filing: 2019/04/11
Last earnings reported: 2019/02/28
Last annual earnings reported: 2018/11/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.